Comparison between Betamethasone, Fluorometholone and Loteprednol Etabonate on intraocular pressure in patients after keratorefractive surgery
- PMID: 29988925
- PMCID: PMC6033780
- DOI: 10.1016/j.joco.2017.11.008
Comparison between Betamethasone, Fluorometholone and Loteprednol Etabonate on intraocular pressure in patients after keratorefractive surgery
Abstract
Purpose: The aim of this study was to compare the ocular hypertensive effect of the commercially available Betamethasone, Fluorometholone in Iran and Loteprednol Etabonate in patients undergoing keratorefractive surgery.
Methods: In this prospective randomized clinical trial, 300 eyes of 150 patients were included, and patients were randomly assigned to 3 groups and used one of the 3 steroid drops (Betamethasone 0.1%, Fluorometholone 0.1%, and Loteprednol Etabonate 0.5%) after myopic photorefractive keratectomy (PRK). Intraocular pressure (IOP) was measured 2, 4, and 6 weeks post-surgery. Twenty-two mmHg was set as the threshold IOP for starting anti-glaucoma medication and tapering steroid drops.
Results: Of 300 eyes from 150 patients over the first 6 postoperative weeks, 2 eyes in Fluorometholone group (2%), 12 eyes in Betamethasone group (12%), and 16 eyes in Loteprednol group (16%) had IOP equal or more than 22 mmHg. Analysis of variance (ANOVA) test showed that the rise in IOP was significantly different between groups in the 2nd and 4th (P ≤ 0.001) postoperative weeks but not at 6th week (P = 0.230). An IOP rise equal or more than 10 mmHg was detected in 13 and 15 eyes in Betamethasone and Loteprednol groups, respectively. None of the eyes in Fluorometholone group had such an IOP rise.
Conclusions: Loteprednol and Fluorometholone were associated with the most and least increase in IOP, respectively. The highest pressures were detected 4 weeks after surgery in the Betamethasone and Loteprednol groups and 6 weeks after surgery in the Fluorometholone group. Fluorometholone was the safest among the three examined steroid drops in terms of IOP rise.
Keywords: Keratorefractive surgery; Loteprednol etabonate; Photorefractive keratectomy; Steroid induced glaucoma.
Figures
Similar articles
-
Comparison of Loteprednol with Fluorometholone after Myopic Photorefractive Keratectomy.J Ophthalmic Vis Res. 2017 Jan-Mar;12(1):11-16. doi: 10.4103/2008-322X.200161. J Ophthalmic Vis Res. 2017. PMID: 28299001 Free PMC article.
-
Efficacy and Safety of Loteprednol 0.5% and Fluorometholone 0.1% After Strabismus Surgery in Children.J Ocul Pharmacol Ther. 2018 Jul/Aug;34(6):468-476. doi: 10.1089/jop.2017.0145. Epub 2018 Jun 29. J Ocul Pharmacol Ther. 2018. PMID: 29958057
-
Efficacy and safety of a 3-month loteprednol etabonate 0.5% gel taper for routine prophylaxis after photorefractive keratectomy compared to a 3-month prednisolone acetate 1% and fluorometholone 0.1% taper.Clin Ophthalmol. 2017 Jun 12;11:1113-1118. doi: 10.2147/OPTH.S138272. eCollection 2017. Clin Ophthalmol. 2017. PMID: 28652697 Free PMC article.
-
Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use.Int Ophthalmol. 2012 Oct;32(5):507-17. doi: 10.1007/s10792-012-9589-2. Epub 2012 Jun 16. Int Ophthalmol. 2012. PMID: 22707339 Free PMC article. Review.
-
Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure.Adv Ther. 2016 Apr;33(4):532-52. doi: 10.1007/s12325-016-0315-8. Epub 2016 Mar 17. Adv Ther. 2016. PMID: 26984315 Free PMC article. Review.
Cited by
-
Efficacy and safety of loteprednol etabonate versus fluorometholone in the treatment of patients after corneal refractive surgery: a meta-analysis.Int Ophthalmol. 2023 Jul;43(7):2477-2486. doi: 10.1007/s10792-023-02646-w. Epub 2023 Mar 4. Int Ophthalmol. 2023. PMID: 36869982
-
Topical Anti-Inflammatory Agents for Non-Infectious Uveitis: Current Treatment and Perspectives.J Inflamm Res. 2022 Nov 28;15:6439-6451. doi: 10.2147/JIR.S288294. eCollection 2022. J Inflamm Res. 2022. PMID: 36467992 Free PMC article. Review.
-
Efficacy of Topical Administration of Corticosteroids for the Management of Dry Eye Disease: Systematic Review and Meta-Analysis.Life (Basel). 2022 Nov 19;12(11):1932. doi: 10.3390/life12111932. Life (Basel). 2022. PMID: 36431067 Free PMC article. Review.
-
New applanation tonometer for myopic patients after laser refractive surgery.Sci Rep. 2020 Apr 27;10(1):7053. doi: 10.1038/s41598-020-64013-4. Sci Rep. 2020. PMID: 32341434 Free PMC article.
-
Effectiveness of Topical Ganciclovir 2% Monotherapy Versus Combined Steroid Therapy in Cytomegalovirus Endotheliitis.J Clin Med. 2022 Sep 30;11(19):5811. doi: 10.3390/jcm11195811. J Clin Med. 2022. PMID: 36233679 Free PMC article.
References
-
- Francois J. Corticosteroid glaucoma. Ann Ophthalmol. 1977;9(9):1075–1080. - PubMed
-
- Armaly M.F. Effect of corticosteroids on intraocular pressure and fluid dynamics: I. The effect of dexamethasone in the normal eye. Arch Ophthalmol. 1963;70:482–491. - PubMed
-
- Wilson K., McCartney M.D., Miggans S.T., Clark A.F. Dexamethasone induced ultrastructural changes in cultured human trabecular meshwork cells. Curr Eye Res. 1993;12(9):783–793. - PubMed
-
- Tripathi B.J., Tripathi R.C., Swift H.H. Hydrocortisone-induced DNA endoreplication in human trabecular cell in vitro. Exp Eye Res. 1989;49(2):259–270. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources